CoChat

Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis

Fountoulakis, Konstantinos N., Saitis, Athanasios, Schatzberg, Alan F. · 2025 · American Journal of Psychiatry

The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects. METHODS: MEDLINE was searched with the keyword "esketamine" on March 24, 2024, using the PRISMA method. Data processing and statistical analysis were performed with R, version 4.3.3, and the meta-analysis was performed with the METAFOR package. RESULTS: Of 1,115 articles initially identified, 87 were included for analysis and discussion. At weeks 2-4, randomized controlled trials were mostly negative or failed; however, the meta-analysis returned a weak but significant positive effect for depression (effect size range, 0.15-0.23 at weeks 2-4), similar to augmentation strategies with atypical antipsychotics for treatment-resistant depression. The effect size concerning suicidality was not significant at any time point. The sensitivity analysis produced the same results. CONCLUSIONS: The study findings suggest that esketamine's efficacy as an add-on to antidepressants is modest in treatment-resistant depression (similar to augmentation strategies with atypical antipsychotics) and is absent against suicidality itself. These findings need to be considered in light of esketamine's abuse potential and the fact that long-term effects are still not fully known. Some alarming signs concerning deaths and emerging suicidality during the testing phase are discussed, along with other regulatory issues.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.20240515

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 133 references

Research works printed but not linked: 5

  1. Kohrs R, 1998, Anesth Analg, 87, 1186
  2. Huang X, 2006, AMIA Annu Symp Proc, 2006, 359
  3. Turkoz I, 2022, CNS Spectr, 28, 1
  4. Echegaray MVF, Trends Psychiatry Psychother
  5. Sapkota A, 2021, Cureus, 13, e17352

Cited by

See all 90

Metadata

Authors
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F.
Affiliations
  • 3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece (Fountoulakis, Saitis); Stanford University Mood Disorders Center and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford (Schatzberg).
  • Aristotle University of Thessaloniki (GR)
Venue
American Journal of Psychiatry
Published
2025-03-01
Volume
182
Issue
3
Pages
259-275
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W4406934817
Cited by
90
References
133
Citations by year
2026: 51 · 2025: 38
FWCI
11.95
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
esketamine, treatment-resistant depression, major depressive disorder, suicidal ideation, adjunctive therapy, atypical antipsychotics, antidepressant augmentation, adverse drug reactions, abuse liability
MeSH terms
Administration, Intranasal, Adult, Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic, Suicidal Ideation, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1176/appi.ajp.20240515
The paper
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025). Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20240515

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.